Enhancing Chemotherapy in Pancreatic Cancer with LY294002
Author Information
Author(s): Fujiwara Masao, Izuishi Kunihiko, Sano Takanori, Hossain Mohammad Akram, Kimura Shoji, Masaki Tsutomu, Suzuki Yasuyuki
Primary Institution: Kagawa University
Hypothesis
Can the PI3K inhibitor LY294002 enhance the effectiveness of cisplatin in treating pancreatic cancer?
Conclusion
The combination of LY294002 and cisplatin significantly improves the anti-tumor effects against pancreatic cancer cells.
Supporting Evidence
- Cisplatin alone inhibited tumor growth, but the combination with LY294002 was more effective.
- LY294002 increased apoptosis in pancreatic cancer cells when used with cisplatin.
- No significant side effects were observed in mice treated with the combination therapy.
Takeaway
This study found that using a drug called LY294002 with another drug, cisplatin, helps fight pancreatic cancer better than using cisplatin alone.
Methodology
The study used both in vitro cell line experiments and in vivo mouse models to assess the effects of LY294002 and cisplatin on pancreatic cancer cells.
Limitations
The study primarily focused on specific cell lines and a mouse model, which may not fully represent human pancreatic cancer.
Participant Demographics
The study involved human pancreatic cancer cell lines and nude mice.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website